ISCHEMIA Trial: Was It Worth the Wait?

Rasha Al-Lamee, MBBS, MA, PhD; Alice K. Jacobs, MD


Circulation. 2020;142(5):517-519. 

In This Article

Abstract and Introduction


The benefits of revascularization across the spectrum of coronary artery disease acuity differ. Although revascularization in acute coronary syndromes and ST-segment–elevation myocardial infarction (MI) decreases mortality and recurrent MI, outcomes in stable ischemic heart disease (SIHD) are less certain.

Although unblinded data show improvement in symptom relief and quality of life for patients with SIHD treated with revascularization,[1,2] the first placebo-controlled trial of percutaneous coronary intervention showed that the effect of percutaneous coronary intervention on symptoms was smaller than expected.[3] No trial has shown a reduction in cardiovascular mortality or MI after revascularization for SIHD.[1,2]